DK2515899T3 - Fremgangsmåder og sammensætninger til kardiovaskulære sygdomme og tilstande - Google Patents

Fremgangsmåder og sammensætninger til kardiovaskulære sygdomme og tilstande Download PDF

Info

Publication number
DK2515899T3
DK2515899T3 DK10840169.6T DK10840169T DK2515899T3 DK 2515899 T3 DK2515899 T3 DK 2515899T3 DK 10840169 T DK10840169 T DK 10840169T DK 2515899 T3 DK2515899 T3 DK 2515899T3
Authority
DK
Denmark
Prior art keywords
leu
patient
pro
ala
gly
Prior art date
Application number
DK10840169.6T
Other languages
English (en)
Inventor
Michael R Bristow
J David Port
Original Assignee
Arca Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arca Biopharma Inc filed Critical Arca Biopharma Inc
Application granted granted Critical
Publication of DK2515899T3 publication Critical patent/DK2515899T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G01N2333/90248—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13
    • G01N2333/90251—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13 with a definite EC number (1.14.13.-)
    • G01N2333/90254—Nitric-oxide synthase (NOS; 1.14.13.39)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Claims (15)

1. Forbindelsen S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat til anvendelse i behandling af en kardiovaskulær sygdom eller tilstand, hvor en effektiv mængde af en farmaceutisk sammensætning omfattende denne forbindelse administreres til patienten efter at patienten er blevet testet og bestemt til at være homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen.
2. Anvendelse af forbindelsen S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat til fremstilling afen farmaceutisk sammensætning til behandling afen kardiovaskulær sygdom eller tilstand, hvor en effektiv mængde af en farmaceutisk sammensætning omfattende denne forbindelse administreres til patienten efter at patienten er blevet testet og bestemt til at være homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen.
3. Forbindelsen til anvendelse ifølge krav 1 eller anvendelsen ifølge krav 2, hvor den kardiovaskulære sygdom eller tilstand er perifer arteriesygdom, hjertefejl, koronar hjertesygdom, koronar spasme, myokardial infarkt, atherosclerose, eller pulmonær arterial hypertension.
4. Forbindelsen til anvendelse ifølge krav 1 eller 3 eller anvendelsen ifølge krav 2 eller 3, hvor mindst én dosis af sammensætningen skal administreres til patienten, hvor sammensætningen omfatter ca. 1-40 mg af forbindelsen, eller hvor sammensætningen omfatter ca. 5-20 mg af forbindelsen.
5. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1, 3 og 4 eller anvendelsen ifølge et hvilket som helst af kravene 2 til 4, hvor flere doser af sammensætningen skal administreres til patienten.
6. Forbindelsen til anvendelse eller anvendelsen ifølge krav 5, hvor flere doser af sammensætningen i en 24-timers periode eller hvor 1 til 3 doser af sammensætningen, hvor sammensætningen omfatter ca. 1-40 mg of forbindelsen, skal administreres til patienten.
7. Forbindelsen til anvendelse ifølge krav 1 eller anvendelsen ifølge krav 2, hvor patienten er blevet testet for at bestemme patientens genotype ved position 894 i NOS3-genet efter at have været forsynet med eller leveret en biologisk prøve fra patienten.
8. Forbindelsen til anvendelse ifølge krav 1 eller anvendelsen ifølge krav 2, hvor patientens genotype ved position 894 i NOS3-genet er blevet bestemt efter en test er blevet bestilt. 9. S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat til anvendelse i behandling af en patient der er blevet diagnosticeret med en sygdom eller tilstand associeret med NO-produktion, hvor sygdommen er en iskæmisk kardiovaskulær lidelse, glaukom, eller en tarmlidelse, hvor en effektiv mængde af S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat administreres til patienten efter at patienten er blevet testet og bestemt til at være homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen.
10. Anvendelse af S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat til fremstilling af en farmaceutisk sammensætning til behandling af en patient der er blevet diagnosticeret med en sygdom eller tilstand associeret med NO-produktion, hvor sygdommen er en iskæmisk kardiovaskulær lidelse, glaukom, eller en tarmlidelse, hvor en effektiv mængde af S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat administreres til patienten efter at patienten er blevet testet og bestemt til at være homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen. 11. S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat til anvendelse til at øge nitrogenoxid-(NO)-niveauer i en patient der er blevet diagnosticeret med en sygdom eller tilstand associeret med NO-produktion, hvor sygdommen er en iskæmisk kardiovaskulær lidelse, glaukom, eller en tarmlidelse, hvor en effektiv mængde af nævnte S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetatet administreres til patienten efter at patienten er blevet testet og bestemt til at være homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen.
12. Anvendelse af S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat til fremstilling af en farmaceutisk sammensætning til at øge nitrogenoxid-(NO) niveauer i en patient der er blevet diagnosticeret med en sygdom eller tilstand associeret med NO-produktion, hvor sygdommen er en iskæmisk kardiovaskulær lidelse, glaukom, eller en tarmlidelse, hvor en effektiv mængde af nævnte S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat administreres til patienten efter at patienten er blevet testet og bestemt til at være homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen.
13. En in vitro-fremgangsmåde til identificering om en patient er egnet til behandling med S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat omfattende bestemmelse af hvorvidt patienten er homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen, hvor patienten er er egnet til behandling med S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat hvis patienten er homozygot vildtype (G/G) ved position 894 i NOS3-genet.
14. Fremgangsmåde til diagnosticering af en patient som en egnet kandidat til behandling med S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat omfattende analysering af en prøve fra patienten for at bestemme hvorvidt patienten er homozygot vildtype (G/G) ved position 894 i det endoteliale nitrogenoxidsyntase-(NOS3)-gen og rapportering om patienten er homozygot vildtype (G/G) ved position 894 i NOS3-genet.
15. Anvendelse af et kit til at identificere om en patient er egnet til behandling med S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat eller til diagnosticering afen patient som en egnet kandidat til behandling med S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-l-il)thioacetat, hvor dette kit omfatter i en egnet beholder en sonde eller mindst ét sæt primere til at identificere NOS3-polymorfisme ved position 894.
16. Anvendelsen ifølge krav 15, hvor sonden omfatter mindst én nukleinsyre på mellem 15 og 100 nukleotider af SEQ ID NO:l og/eller SEQ ID NO:3, hvor sonden omfatter nukleotidet ved position 894 af NOS3-genet.
17. Anvendelsen ifølge krav 15, hvor primerne omfatter mindst ét sæt primere til at amplificere en sekvensregion der omfatter position 894 af NOS3-genet.
DK10840169.6T 2009-12-23 2010-12-23 Fremgangsmåder og sammensætninger til kardiovaskulære sygdomme og tilstande DK2515899T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28993209P 2009-12-23 2009-12-23
PCT/US2010/062023 WO2011079273A2 (en) 2009-12-23 2010-12-23 Methods and compositions for cardiovascular diseases and conditions

Publications (1)

Publication Number Publication Date
DK2515899T3 true DK2515899T3 (da) 2016-08-15

Family

ID=44196415

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10840169.6T DK2515899T3 (da) 2009-12-23 2010-12-23 Fremgangsmåder og sammensætninger til kardiovaskulære sygdomme og tilstande

Country Status (6)

Country Link
US (1) US20130131161A1 (da)
EP (1) EP2515899B1 (da)
CA (1) CA2822747A1 (da)
DK (1) DK2515899T3 (da)
ES (1) ES2587191T3 (da)
WO (1) WO2011079273A2 (da)

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001011A1 (en) 1980-09-24 1982-04-01 Corp Cetus Diagnostic method and probe
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4946773A (en) 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
ATE88761T1 (de) 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4627429A (en) 1986-02-28 1986-12-09 American Home Products Corporation Storage-stable transdermal adhesive patch
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4784857A (en) 1986-06-03 1988-11-15 Smith And Nephew Associated Companies Plc Drug delivery device, its preparation and use
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US4816571A (en) 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
AU624601B2 (en) 1988-01-21 1992-06-18 Genentech Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5932413A (en) 1988-04-01 1999-08-03 Celebuski; Joseph Eugene DNA probe assay using neutrally charged probe strands
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
US5858652A (en) 1988-08-30 1999-01-12 Abbott Laboratories Detection and amplification of target nucleic acid sequences
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5849481A (en) 1990-07-27 1998-12-15 Chiron Corporation Nucleic acid hybridization assays employing large comb-type branched polynucleotides
US5645987A (en) 1990-09-21 1997-07-08 Amgen Inc. Enzymatic synthesis of oligonucleotides
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5849486A (en) 1993-11-01 1998-12-15 Nanogen, Inc. Methods for hybridization analysis utilizing electrically controlled hybridization
US5846708A (en) 1991-11-19 1998-12-08 Massachusetts Institiute Of Technology Optical and electrical methods and apparatus for molecule detection
DE4204650C1 (da) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
ATE253645T1 (de) 1992-04-01 2003-11-15 Univ Johns Hopkins Med Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien
US5428148A (en) 1992-04-24 1995-06-27 Beckman Instruments, Inc. N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
US5843640A (en) 1992-06-19 1998-12-01 Northwestern University Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells
US5861244A (en) 1992-10-29 1999-01-19 Profile Diagnostic Sciences, Inc. Genetic sequence assay using DNA triple strand formation
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5658751A (en) 1993-04-13 1997-08-19 Molecular Probes, Inc. Substituted unsymmetrical cyanine dyes with selected permeability
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
GB9311386D0 (en) 1993-06-02 1993-07-21 Pna Diagnostics As Nucleic acid analogue assay procedures
US5846709A (en) 1993-06-15 1998-12-08 Imclone Systems Incorporated Chemical process for amplifying and detecting nucleic acid sequences
FR2708288B1 (fr) 1993-07-26 1995-09-01 Bio Merieux Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé.
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
GB2284208A (en) 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
DE69432919T2 (de) 1993-12-28 2004-05-27 Tanabe Seiyaku Co., Ltd. Verfahren für den Nachweis spezifischer Polynukleotiden
AU694187B2 (en) 1994-02-07 1998-07-16 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis TM of single nucleotide polymorphisms and its use in genetic analysis
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5851770A (en) 1994-04-25 1998-12-22 Variagenics, Inc. Detection of mismatches by resolvase cleavage using a magnetic bead support
NZ287118A (en) 1994-05-28 1999-01-28 Tepnel Medical Ltd Method of detecting and amplifying oligonucleotides
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
US5849483A (en) 1994-07-28 1998-12-15 Ig Laboratories, Inc. High throughput screening method for sequences or genetic alterations in nucleic acids
ATE226983T1 (de) 1994-08-19 2002-11-15 Pe Corp Ny Gekoppeltes ampflikation- und ligationverfahren
US5574146A (en) 1994-08-30 1996-11-12 Beckman Instruments, Inc. Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US5599668A (en) 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
US5554744A (en) 1994-09-23 1996-09-10 Hybridon, Inc. Method for loading solid supports for nucleic acid synthesis
EP0709466B1 (en) 1994-10-28 2006-09-27 Gen-Probe Incorporated Compositions and methods for the simultaneous detection and quantification of multiple specific nucleic acid sequences
US5935825A (en) 1994-11-18 1999-08-10 Shimadzu Corporation Process and reagent for amplifying nucleic acid sequences
WO1996019205A1 (en) 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
US5866337A (en) 1995-03-24 1999-02-02 The Trustees Of Columbia University In The City Of New York Method to detect mutations in a nucleic acid using a hybridization-ligation procedure
US5843650A (en) 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
US5929227A (en) 1995-07-12 1999-07-27 The Regents Of The University Of California Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores
US5916779A (en) 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
US5866331A (en) 1995-10-20 1999-02-02 University Of Massachusetts Single molecule detection by in situ hybridization
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
NZ322185A (en) * 1995-11-13 1999-05-28 Shionogi & Co Diagnosis of coronary artery spasm-associated diseases by screening for changes in the endothelial nitric oxide synthase gene
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
US5851772A (en) 1996-01-29 1998-12-22 University Of Chicago Microchip method for the enrichment of specific DNA sequences
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5939291A (en) 1996-06-14 1999-08-17 Sarnoff Corporation Microfluidic method for nucleic acid amplification
US5912124A (en) 1996-06-14 1999-06-15 Sarnoff Corporation Padlock probe detection
US5853990A (en) 1996-07-26 1998-12-29 Edward E. Winger Real time homogeneous nucleotide assay
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5849546A (en) 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US5853992A (en) 1996-10-04 1998-12-29 The Regents Of The University Of California Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels
US5853993A (en) 1996-10-21 1998-12-29 Hewlett-Packard Company Signal enhancement method and kit
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US5905024A (en) 1996-12-17 1999-05-18 University Of Chicago Method for performing site-specific affinity fractionation for use in DNA sequencing
US5846729A (en) 1997-02-27 1998-12-08 Lorne Park Research, Inc. Assaying nucleotides in solution using a fluorescent intensity quenching effect
US6113940A (en) 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
US5849497A (en) 1997-04-03 1998-12-15 The Research Foundation Of State University Of New York Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker
US5846726A (en) 1997-05-13 1998-12-08 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5928869A (en) 1997-05-30 1999-07-27 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US5916776A (en) 1997-08-27 1999-06-29 Sarnoff Corporation Amplification method for a polynucleotide
US5935791A (en) 1997-09-23 1999-08-10 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5932451A (en) 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
ES2142773B1 (es) 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
EP1865770A4 (en) * 2005-04-07 2010-12-29 Nitromed Inc EVALUATION OF THE GENETIC RISK OF CARDIAC INSUFFICIENCY: IMPACT OF THE GENETIC VARIATION OF NOS3
US20070254861A1 (en) * 2006-04-28 2007-11-01 Astellas Pharma Inc. Methods for the prevention and/or treatment of peripheral arterial disease
EP1941876A1 (en) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
WO2011079273A3 (en) 2011-11-10
CA2822747A1 (en) 2011-06-30
EP2515899A2 (en) 2012-10-31
EP2515899A4 (en) 2013-07-03
US20130131161A1 (en) 2013-05-23
ES2587191T3 (es) 2016-10-21
WO2011079273A2 (en) 2011-06-30
EP2515899B1 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
US20180156782A1 (en) Methods for Treatment with Bucindolol Based on Genetic Targeting
EP2264183B1 (en) Risk markers for cardiovascular disease
EP2739750B1 (en) Cardiovascular disease
EP3039156B1 (en) Risk markers for cardiovascular disease in patients with chronic kidney disease
US20170081722A1 (en) Polymorphisms in the pde3a gene
US20200239957A1 (en) Prediction and treatment of heart failure
DK2515899T3 (da) Fremgangsmåder og sammensætninger til kardiovaskulære sygdomme og tilstande
AU2011203050B2 (en) Method for treatment with bucindolol based on genetic targeting
CN101087891A (zh) 基于基因靶向使用布新洛尔的治疗方法